Novartis

Explore the latest insights on Novartis and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Novartis’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Fineline Info & Tech (Flcube.com) provides you with comprehensive information about Novartis, including details on the company, its pharmaceuticals, policies, deals, healthcare enterprises, research and development, hospitals, legal patents, and internet healthcare. More information about Novartis please access flcube.com

Biohaven Licenses MoDE Pan‑IgG Degrader Portfolio to Ono Pharmaceutical in Asia – Up to USD 100 Million in Near‑Term Payments for BHV‑1300 Franchise
CompanyDeals

Biohaven Licenses MoDE Pan‑IgG Degrader Portfolio to Ono Pharmaceutical in Asia – Up to USD 100 Million in Near‑Term Payments for BHV‑1300 Franchise

Biohaven Ltd. (NYSE: BHVN) announced that it has entered into a strategic licensing and collaboration agreement with Japan's Ono Pharmaceutical Co., Ltd. (TYO: 4528). Under the agreement, Ono will obtain…

Mirxes Partners with Thailand's National Cancer Institute on Blood‑Based Colorectal Cancer Screening – 2,000‑Subject Prospective Triage Study Backs "Cancer Moonshot 2056"

Mirxes Partners with Thailand’s National Cancer Institute on Blood‑Based Colorectal Cancer Screening – 2,000‑Subject Prospective Triage Study Backs “Cancer Moonshot 2056”

Huadong Medicine's Doer Bio Wins NMPA Clearance to Trial DR30206 – Tri‑Target PD‑L1/VEGF/TGF‑β Fusion Protein Advances into Stage III NSCLC Consolidation Therapy

Huadong Medicine’s Doer Bio Wins NMPA Clearance to Trial DR30206 – Tri‑Target PD‑L1/VEGF/TGF‑β Fusion Protein Advances into Stage III NSCLC Consolidation Therapy

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDeals

Novartis and Fudan University Shanghai Cancer Center Renew Partnership to Drive Precision Cancer Treatments

Company

Novartis Sees Robust Growth in Innovative Medicines with 2023 Financials Reflecting a Shift Toward R&D Focus

CompanyDrug

Novartis Lutathera Combo Therapy Shows Significant Progress in GEP-NETs

CompanyDeals

Novartis Acquires Calypso Biotech for USD 250 Million to Bolster IL-15 Pipeline

CompanyDeals

Cytokinetics Attracts Big Pharma Interest Amid Aficamten’s Phase III Success

CompanyDeals

Alphabet’s Isomorphic Labs Inks Pharma Partnerships with Eli Lilly and Novartis

CompanyDrug

Novartis’s Cosentyx Secures Additional Indication for Psoriatic Arthritis in China

Company

International Society for Cell & Gene Therapy Comments on FDA’s CAR-T Investigation

Show More